Filtered By:
Condition: Heart Failure
Education: Lessons

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 25 results found since Jan 2013.

Who Must We Target Now to Minimize Future Cardiovascular Events and Total Mortality?: Lessons From the Surveillance, Prevention and Management of Diabetes Mellitus (SUPREME-DM) Cohort Study Original Articles
Conclusions— To sustain improvements in myocardial infarction, stroke, heart failure, and mortality, health systems that have successfully focused on care improvement in high-risk adults with DM or CVD must broaden their improvement strategies to target lower risk adults who have not yet developed DM or CVD.
Source: Circulation: Cardiovascular Quality and Outcomes - September 15, 2015 Category: Cardiology Authors: Desai, J. R., Vazquez-Benitez, G., Xu, Z., Schroeder, E. B., Karter, A. J., Steiner, J. F., Nichols, G. A., Reynolds, K., Xu, S., Newton, K., Pathak, R. D., Waitzfelder, B., Elston Lafata, J., Butler, M. G., Kirchner, H. L., Thomas, A., O'Connor, P. J., o Tags: Congestive, Type 2 diabetes, Acute myocardial infarction, Primary and Secondary Stroke Prevention Original Articles Source Type: research

Eulogy For My Father
I thought I would get used to it. Maybe feel some callousness to it. Walking into the building and being directed to the viewing hall. Walking to the front of the room and seeing a loved one lying in a casket. I have seen a cousin, grandparents, uncles and friends within the last five years or so pass away. These past few months I have had to come to grips that I will again face death. My dad is dying! Twenty-four years ago my father suffered a near fatal stroke. The years following have been dealt with his heath declining and new issues he's faced including COPD and congestive heart failure. He has had a portable defibr...
Source: Healthy Living - The Huffington Post - April 8, 2015 Category: Consumer Health News Source Type: news

ESC 2017 Roundup: Biotronik touts lowered mortality for AF patients treated with cath ablation
Biotronik today released results from the Castle-AF study exploring the use of catheter ablation to treat heart failure patients with atrial fibrillation, touting a 38% composite reduction in all-cause mortality and hospitalization for worsening heart failure. The 398-patient, 33-site study compared the results of catheter ablation treatment for AF in heart failure patients using implantable cardioverter defibrillators or cardiac resynchronization therapy defibrillators to standard-of-care pharmacological therapy, the company said. Biotronik touted it as the largest study of its kind to date. Results indicated a 47% reduc...
Source: Mass Device - August 28, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Assist Devices Cardiac Implants Cardiovascular Clinical Trials Biotronik Medtronic Source Type: news

Freedom in waiting: A ventricular assist device gives Aidan’s family independence
Aidan When Aidan was just 8 months old, his parents Patrick and Tavina received shocking news—their son had hypertrophic cardiomyopathy, a rare but serious disease that affects the muscle of the heart. Given his young age and severity of his condition, the early prognosis was bleak. “Things didn’t look good at first,” remembers Patrick. “We were steeling ourselves for the real possibility that Aidan wouldn’t make it to see his first birthday.” But, heart condition or not, little Aidan was a fighter, and with minimal medical management his condition stabilized. Over the years, he grew ...
Source: Thrive, Children's Hospital Boston - July 3, 2013 Category: Pediatrics Authors: Tripp Underwood Tags: All posts Heart conditions Our patients’ stories Christina VanderPluym Heart Center heart transplant hypertrophic cardiomyopathy MD VAD ventricular assist device Source Type: news

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
Although cardiovascular (CV) mortality is the principal cause of death in individuals with type 2 diabetes (T2DM), reduction of plasma glucose concentration has little effect on CV disease (CVD) risk. Thus, novel strategies to reduce CVD risk in T2DM patients are needed. The recently published BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) study demonstrated that in T2DM patients with high CVD risk empagliflozin reduced the primary major adverse cardiac event end point (CV death, nonfatal myocardial infarction, nonfatal stroke) by 14%. This beneficial eff...
Source: Diabetes Care - April 20, 2016 Category: Endocrinology Authors: Abdul-Ghani, M.; Del Prato, S.; Chilton, R.; DeFronzo, R. A. Tags: Cardiovascular Disease and Diabetes Source Type: research

Advice For A Happy, Healthy Life From A Man Dedicated To Those Pursuits
Why do you what you do? Can you trace the source of your professional motivation to a single event or person? As CEO of the American Heart Association and American Stroke Association, I'm privileged to interact with many amazing leaders in cardiovascular medicine, technology, business and beyond. I'm always fascinated by the backstory of how each chose the path into a particular field. When it comes to medical professionals, some simply love the science. Others are drawn by the desire to help people. And then there are those to whom it's personal. Dr. Steven Houser fits all three categories. After four years of playin...
Source: Healthy Living - The Huffington Post - November 22, 2016 Category: Consumer Health News Source Type: news

Cells to Society: Year of the Nurse / Global Impact
This study establishes baseline sociodemographic and clinical characteristics of hospitalized patients in Nepal who were experiencing heart failure.     Read more   Maternal Health ...
Source: Johns Hopkins University and Health Systems Archive - February 6, 2020 Category: Nursing Source Type: news

Intracardiac thrombus in a patient with mitral bioprosthesis and atrial fibrillation treated with direct oral anticoaugulant: A case report
Rationale: Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with increased morbidity, especially stroke and heart failure. There is also increasing awareness that atrial fibrillation is a major cause of embolic events which in 75% of cases are complicated by cerebrovascular accidents. Patient concerns: A 50-year-old woman with mitral bioprosthesis under warfarin for nonvalvular atrial fibrillation was referred to our Coronary Intensive Care Unit due to acute myocardial infarction without evidence of significant coronary artery stenosis. Diagnoses: Cardiovascular examination...
Source: Medicine - June 11, 2021 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

11 Hospice and palliative care for advanced cardiac diseases in hong kong
Advanced cardiac diseases are common non-cancer conditions that require good palliative care. Palliative Care should embrace both cancer and non-cancer conditions, and is applicable early in the course of illness, in conjunction with other therapies. There is a high prevalence of symptoms and distress in heat failure (HF) necessitating palliative care, which include not just dyspnoea and oedema but also a range of other symptoms that are all sub-optimally controlled at the end of life.1 For patients with HF, palliative care attends to physical, psychological, social and spiritual distress, caring for both patients and fam...
Source: Heart Asia - April 24, 2019 Category: Cardiology Authors: Lo, R. S. Tags: Keynote Lecture Source Type: research

A new look at atrial fibrillation: lessons learned from drugs, pacing, and ablation therapies
Atrial fibrillation (AF) is the most common arrhythmia and among the leading causes of stroke and heart failure in Western populations. Despite the increasing size of clinical trials assessing the efficacy and safety of AF therapies, achieved outcomes have not always matched expectations. Considering that AF is a symptom of many possible underlying diseases, clinical research for this arrhythmia should take into account their respective pathophysiology. Accordingly, the definition of the study populations to be included should rely on the established as well as on the new classifications of AF and take advantage from a dif...
Source: European Heart Journal - September 14, 2013 Category: Cardiology Authors: Kappenberger, L. Tags: REVIEWS Source Type: research

Hypertension in Haiti: The Challenge of Best Possible Practice
On the fourth anniversary, it is impossible to discuss hypertension in Haiti without acknowledging the almost incalculable negative impact of the January 12, 2010 earthquake. It was catastrophic not only in terms of death and physical injury, but also the widespread destruction of a tenuous infrastructure and public health system. Yet, paradoxically, this virtual blank slate could be an opportunity to develop an innovative pragmatic approach to the equally devastating problem of hypertension as the most common contributing cause of death in Haiti. Rising Phoenix‐like literally from the ashes and rubble, there are lessons...
Source: The Journal of Clinical Hypertension - January 1, 2014 Category: Cardiology Authors: John G. Kenerson Tags: Review Paper Source Type: research

Erythropoietin and organ protection: lessons from negative clinical trials
Based on its pleiotropic effects, erythropoietin can decrease inflammation, oxidative stress, and apoptosis. Erythropoietin provides organ protection for the heart, brain, and kidney in diverse preclinical animal studies, especially models that include ischemia–reperfusion injury and/or inflammation. However, large clinical studies in coronary reperfusion, heart failure, stroke, acute kidney injury, and chronic renal disease have failed to demonstrate improved outcomes. A study in a previous issue of Critical Care examining the ability of erythropoietin to prevent or ameliorate acute kidney injury in patients undergoing ...
Source: Critical Care - September 11, 2014 Category: Intensive Care Authors: Ronald Pearl Source Type: research

Lessons Learned from 150 Continuous-Flow Left Ventricular Assist Devices: A Single Institutional 7 Year Experience
Continuous-flow (CF) left ventricular assist devices (LVADs) have become the standard of care for patients with advanced heart failure refractory to optimal medical therapy. The goal of this study was to review our 7 year single institutional experience with CF LVADs. Mean age was 50.4 + 12.5 (17–69) years for bridge-to-transplantation (BTT) patients and 57.6 + 10.4 (31–81) years for destination therapy (DT) patients (p
Source: ASAIO Journal - May 1, 2015 Category: Medical Equipment Tags: Adult Circulatory Support Source Type: research

Prognostic and symptomatic benefits with ivabradine: lessons from the SHIFT trial
Ivabradine, a funny current (If) inhibitor, has been developed for symptomatic therapy of angina and in chronic heart failure (CHF) with low ejection fraction. A large outcome trial, SHIFT (Systolic Heart Failure Treatment with the If inhibitor ivabradine trial), was conducted in patients with EF ≤ 35% in sinus rhythm and increased heart rate ≥70 b.p.m. It demonstrated that the addition of this new compound to the best possible contemporary therapy, including beta-blockers, was associated with a 18% relative risk reduction in the occurrence of cardiovascular mortality or hospitalization for worsening heart failure (H...
Source: European Journal of Heart Failure Supplements - December 16, 2015 Category: Cardiology Authors: Komajda, M. Tags: Articles Source Type: research

Early Lessons on Bundled Payment at an Academic Medical Center.
CONCLUSION: Opportunities for savings under bundled payment may be greater for lower extremity joint arthroplasty than for other conditions. PMID: 28837458 [PubMed - in process]
Source: The Journal of the American Academy of Orthopaedic Surgeons - August 25, 2017 Category: Orthopaedics Tags: J Am Acad Orthop Surg Source Type: research